Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 30;24(11):9489.
doi: 10.3390/ijms24119489.

The Mechanism of Action and Clinical Efficacy of Low-Dose Long-Term Macrolide Therapy in Chronic Rhinosinusitis

Gwanghui Ryu  1 , Eunkyu Lee  1 , Song I Park  2 , Minhae Park  1 , Sang Duk Hong  1 , Yong Gi Jung  1 , Hyo Yeol Kim  1
Affiliations
Review

The Mechanism of Action and Clinical Efficacy of Low-Dose Long-Term Macrolide Therapy in Chronic Rhinosinusitis

Gwanghui Ryu et al. Int J Mol Sci. .

Abstract

Various chronic inflammatory airway diseases can be treated with low-dose, long-term (LDLT) macrolide therapy. LDLT macrolides can be one of the therapeutic options for chronic rhinosinusitis (CRS) due to their immunomodulatory and anti-inflammatory actions. Currently, various immunomodulatory mechanisms of the LDLT macrolide treatment have been reported, as well as their antimicrobial properties. Several mechanisms have already been identified in CRS, including reduced cytokines such as interleukin (IL)-8, IL-6, IL-1β, tumor necrosis factor-α, transforming growth factor-β, inhibition of neutrophil recruitment, decreased mucus secretion, and increased mucociliary transport. Although some evidence of effectiveness for CRS has been published, the efficacy of this therapy has been inconsistent across clinical studies. LDLT macrolides are generally believed to act on the non-type 2 inflammatory endotype of CRS. However, the effectiveness of LDLT macrolide treatment in CRS is still controversial. Here, we reviewed the immunological mechanisms related to CRS in LDLT macrolide therapy and the treatment effects according to the clinical situation of CRS.

Keywords: chronic rhinosinusitis; cytokines; macrolide; nasal polyps; neutrophils.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanism of action and clinical implications of low-dose, long-term macrolide therapy in chronic rhinosinusitis.
See this image and copyright information in PMC

References

    1. Kudoh S., Azuma A., Yamamoto M., Izumi T., Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am. J. Respir. Crit. Care Med. 1998;157:1829–1832. - PubMed
    1. Kricker J.A., Page C.P., Gardarsson F.R., Baldursson O., Gudjonsson T., Parnham M.J. Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development. Pharmacol. Rev. 2021;73:233–262. - PubMed
    1. Smith D., Du Rand I.A., Addy C., Collyns T., Hart S., Mitchelmore P., Rahman N., Saggu R. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. BMJ Open Respir. Res. 2020;7:e000489. - PMC - PubMed
    1. Kanoh S., Rubin B.K. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 2010;23:590–615. - PMC - PubMed
    1. Culić O., Eraković V., Parnham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur. J. Pharmacol. 2001;429:209–229. - PubMed